Pharmacologic management of heart failure with preserved ejection fraction

Annals of Pharmacotherapy

Volumn 44, Issue 12, 2010, Pages 1933-1945

  Huang, Dana ^a   Cheng, Judy W M ^b,c  

^a BAYER CORPORATION   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

blockers; Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Diastolic dysfunction; Heart failure with preserved ejection fraction; Pharmacologic management

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; NEBIVOLOL; PERINDOPRIL; PLACEBO; PROPRANOLOL; QUINAPRIL; RAMIPRIL; VALSARTAN; VASODILATOR AGENT; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; ARTICLE; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DIGOXIN; HEART FAILURE, DIASTOLIC; HUMANS; STROKE VOLUME;

EID: 78649909543     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P372     Document Type: Article

References (36)

1. Aurigemma GP, Zile MR, Gaasch WH. Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation 2006;113:296-304.
2. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479.
3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9.
4. Jones CR, Francis GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigational Group Trial. J Am Coll Cardiol 2004;44:1025-9.
5. Heart Failure Society of America. 2010 HFSA heart failure practice guidelines. Section 11: evaluation and management of patients with heart failure and preserved left ventricular ejection fraction. J Card Fail 2010;16:e126-33.
6. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. The prevalence of left ventricular diastolic filling abnormalities in patients with suspected heart failure. Eur Heart J 1997;18:981-4.
7. Burkhoff D, Maurer MS, Packer M. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? Circulation 2003;107:656-8.
8. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure; part I: diagnosis, prognosis and measurements of diastolic function. Circulation 2002;105:1387-93.
9. Cheng JWM, Nayar M. A review of heart failure management in elderly population. Am J Geriatr Pharmacother 2009;7:1-17.
10. Mendes LA, Davidoff R, Cupples LA, Ryan TJ, Jacobs AK. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997;134:207-12.
11. Masoudi FA, Havranek EP, Smith G, et al. Gender, age and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003;41:217-23.
12. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission and functional decline. J Am Coll Cardiol 2003;41:1510-8.
13. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-27.
14. Konstam MA. Systolic and diastolic dysfunction in heart failure? Time for a new paradigm. J Card Fail 2003;9:1-3.
15. Vasab RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118-21.
16. van Kraaij DJ, can Pol PE, Ruiters AW, et al. Diagnosing diastolic heart failure. Eur J Heart Fail 2002;4:419-30.
17. Hogg K, McMurray J. The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). Heart Failure Rev 2006;11:141-6.
18. Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 1999;10:S258-65.
19. Cleland JG, Tendera M, Adamus J, et al.; PEP-CHF investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45.
20. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993;71:602-4.
21. Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther 2003;17:133-9.
22. Lang CC, McAlpine HM, Kennedy N, Rahman AR, Lipworth BJ, Struthers AD. Effects of lisinopril on congestive heart failure in normotensive patients with diastolic dysfunction but intact systolic function. Eur J Clin Pharmacol 1995;49:15-9.
23. Bennett KM, Hernandez AF, Chen AY, et al. Heart failure with preserved left ventricular systolic function among patients with non-ST segment elevation acute coronary syndromes. Am J Cardiol 2007;99:1351-6.
24. Yusuf S, Pfeffer MA, Swedberg K, et al.; CHARM investigators and committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
25. Massie BM, Carson PE, McMurray JJ, et al. ; I-PRESERVE investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67.
26. Yip GW, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study: a randomized controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008;94:573-80. (Pubitemid 351580128)
27. Parthasarathy HK, Pieske B, Weisskopf M, et al. A randomized, doubleblind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. Eur J Heart Fail 2009;1:980-9.
28. Warner JG Jr, Metzger DC, Kitzman DW, Wesley DJ, Little WC. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999;33:1567-72.
29. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
30. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997;80:207-9. (Pubitemid 27329224)
31. Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004;94:448-53.
32. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990;66:981-6.
33. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
34. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006;114:397-403. (Pubitemid 44264821)
35. Aldosterone antagonist therapy for adults with heart failure and preserved systolic function (TOPCAT). http://clinicaltrials.gov/ct2/show/ NCT00094302?term=TOPCAT&rank=1 (accessed 2010 Jun 15).
36. Evaluating the effectiveness of sildenafil at improving health outcomes and exercise ability in people with diastolic heart failure (the RELAX study). http://clinicaltrials.gov/ct2/show/NCT00763867 (accessed 2010 Jun 15).